img

Global Cancer Drug based on PARP Inhibitor Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Drug based on PARP Inhibitor Market Insights, Forecast to 2034

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP)
Global Cancer Drug based on PARP Inhibitor market is expected to reach to US$ 7815.3 million in 2024, with a positive growth of %, compared with US$ 5904.1 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Cancer Drug based on PARP Inhibitor industry is evaluated to reach US$ 13040 million in 2029. The CAGR will be 8.9% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Cancer Drug based on PARP Inhibitor market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Cancer Drug based on PARP Inhibitor market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Merck & Co
GSK
Clovis Oncology
Pfizer
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna

Segment by Application


Ovarian Cancer
Breast Cancer
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Cancer Drug based on PARP Inhibitor plant distribution, commercial date of Cancer Drug based on PARP Inhibitor, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Cancer Drug based on PARP Inhibitor introduction, etc. Cancer Drug based on PARP Inhibitor Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Cancer Drug based on PARP Inhibitor
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Cancer Drug based on PARP Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.3 Market by Application
1.3.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts 2018-2029
2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region
2.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2024)
2.2.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2024-2029)
2.2.4 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2029)
2.3 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts 2018-2029
2.4 Global Cancer Drug based on PARP Inhibitor Sales by Region
2.4.1 Global Cancer Drug based on PARP Inhibitor Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Cancer Drug based on PARP Inhibitor Sales by Region (2018-2024)
2.4.3 Global Cancer Drug based on PARP Inhibitor Sales by Region (2024-2029)
2.4.4 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers
3.1.1 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (2018-2024)
3.1.2 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Drug based on PARP Inhibitor in 2022
3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers
3.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2018-2024)
3.2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Drug based on PARP Inhibitor Revenue in 2022
3.3 Global Key Players of Cancer Drug based on PARP Inhibitor, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Cancer Drug based on PARP Inhibitor Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Offered and Application
3.8 Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Drug based on PARP Inhibitor Sales by Type
4.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Type (2018-2024)
4.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Type (2024-2029)
4.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
4.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type
4.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Type (2018-2024)
4.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Type (2024-2029)
4.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
4.3 Global Cancer Drug based on PARP Inhibitor Price by Type
4.3.1 Global Cancer Drug based on PARP Inhibitor Price by Type (2018-2024)
4.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Cancer Drug based on PARP Inhibitor Sales by Application
5.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Application (2018-2024)
5.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Application (2024-2029)
5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application
5.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Application (2018-2024)
5.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Application (2024-2029)
5.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
5.3 Global Cancer Drug based on PARP Inhibitor Price by Application
5.3.1 Global Cancer Drug based on PARP Inhibitor Price by Application (2018-2024)
5.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Cancer Drug based on PARP Inhibitor Market Size by Type
6.1.1 US & Canada Cancer Drug based on PARP Inhibitor Sales by Type (2018-2029)
6.1.2 US & Canada Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2029)
6.2 US & Canada Cancer Drug based on PARP Inhibitor Market Size by Application
6.2.1 US & Canada Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)
6.2.2 US & Canada Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)
6.3 US & Canada Cancer Drug based on PARP Inhibitor Market Size by Country
6.3.1 US & Canada Cancer Drug based on PARP Inhibitor Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)
6.3.3 US & Canada Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Type
7.1.1 Europe Cancer Drug based on PARP Inhibitor Sales by Type (2018-2029)
7.1.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2029)
7.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Application
7.2.1 Europe Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)
7.2.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)
7.3 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
7.3.1 Europe Cancer Drug based on PARP Inhibitor Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)
7.3.3 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Cancer Drug based on PARP Inhibitor Market Size
8.1.1 China Cancer Drug based on PARP Inhibitor Sales (2018-2029)
8.1.2 China Cancer Drug based on PARP Inhibitor Revenue (2018-2029)
8.2 China Cancer Drug based on PARP Inhibitor Market Size by Application
8.2.1 China Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)
8.2.2 China Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cancer Drug based on PARP Inhibitor Market Size by Type
9.1.1 Asia Cancer Drug based on PARP Inhibitor Sales by Type (2018-2029)
9.1.2 Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2029)
9.2 Asia Cancer Drug based on PARP Inhibitor Market Size by Application
9.2.1 Asia Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)
9.2.2 Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)
9.3 Asia Cancer Drug based on PARP Inhibitor Sales by Region
9.3.1 Asia Cancer Drug based on PARP Inhibitor Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2029)
9.3.3 Asia Cancer Drug based on PARP Inhibitor Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Market Size by Type
10.1.1 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Market Size by Application
10.2.1 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Country
10.3.1 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Overview
11.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 GSK Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GSK Recent Developments
11.4 Clovis Oncology
11.4.1 Clovis Oncology Company Information
11.4.2 Clovis Oncology Overview
11.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Clovis Oncology Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
11.6 Zai Lab
11.6.1 Zai Lab Company Information
11.6.2 Zai Lab Overview
11.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zai Lab Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Drug based on PARP Inhibitor Industry Chain Analysis
12.2 Cancer Drug based on PARP Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Drug based on PARP Inhibitor Production Mode & Process
12.4 Cancer Drug based on PARP Inhibitor Sales and Marketing
12.4.1 Cancer Drug based on PARP Inhibitor Sales Channels
12.4.2 Cancer Drug based on PARP Inhibitor Distributors
12.5 Cancer Drug based on PARP Inhibitor Customers
13 Market Dynamics
13.1 Cancer Drug based on PARP Inhibitor Industry Trends
13.2 Cancer Drug based on PARP Inhibitor Market Drivers
13.3 Cancer Drug based on PARP Inhibitor Market Challenges
13.4 Cancer Drug based on PARP Inhibitor Market Restraints
14 Key Findings in The Global Cancer Drug based on PARP Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Lynparza
Table 3. Major Manufacturers of Zejula
Table 4. Major Manufacturers of Rubraca
Table 5. Major Manufacturers of Talzenna
Table 6. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Cancer Drug based on PARP Inhibitor Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2024)
Table 11. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2024-2029)
Table 12. Global Cancer Drug based on PARP Inhibitor Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Cancer Drug based on PARP Inhibitor Sales by Region (2018-2024) & (K Units)
Table 14. Global Cancer Drug based on PARP Inhibitor Sales by Region (2024-2029) & (K Units)
Table 15. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2024)
Table 16. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2024-2029)
Table 17. Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Cancer Drug based on PARP Inhibitor Sales Share by Manufacturers (2018-2024)
Table 19. Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Cancer Drug based on PARP Inhibitor Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Cancer Drug based on PARP Inhibitor, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Cancer Drug based on PARP Inhibitor Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Cancer Drug based on PARP Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Cancer Drug based on PARP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Drug based on PARP Inhibitor as of 2022)
Table 25. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Product Offered and Application
Table 27. Global Key Manufacturers of Cancer Drug based on PARP Inhibitor, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 30. Global Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 31. Global Cancer Drug based on PARP Inhibitor Sales Share by Type (2018-2024)
Table 32. Global Cancer Drug based on PARP Inhibitor Sales Share by Type (2024-2029)
Table 33. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Cancer Drug based on PARP Inhibitor Revenue Share by Type (2018-2024)
Table 36. Global Cancer Drug based on PARP Inhibitor Revenue Share by Type (2024-2029)
Table 37. Cancer Drug based on PARP Inhibitor Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Cancer Drug based on PARP Inhibitor Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 40. Global Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 41. Global Cancer Drug based on PARP Inhibitor Sales Share by Application (2018-2024)
Table 42. Global Cancer Drug based on PARP Inhibitor Sales Share by Application (2024-2029)
Table 43. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Cancer Drug based on PARP Inhibitor Revenue Share by Application (2018-2024)
Table 46. Global Cancer Drug based on PARP Inhibitor Revenue Share by Application (2024-2029)
Table 47. Cancer Drug based on PARP Inhibitor Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Cancer Drug based on PARP Inhibitor Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Cancer Drug based on PARP Inhibitor Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Cancer Drug based on PARP Inhibitor Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Cancer Drug based on PARP Inhibitor Sales by Country (2024-2029) & (K Units)
Table 62. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 63. Europe Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 64. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 67. Europe Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 68. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2018-2024) & (K Units)
Table 74. Europe Cancer Drug based on PARP Inhibitor Sales by Country (2024-2029) & (K Units)
Table 75. China Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 76. China Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 77. China Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 80. China Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 81. China Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 84. Asia Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 85. Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 88. Asia Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 89. Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Cancer Drug based on PARP Inhibitor Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Cancer Drug based on PARP Inhibitor Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Cancer Drug based on PARP Inhibitor Sales by Region (2018-2024) & (K Units)
Table 95. Asia Cancer Drug based on PARP Inhibitor Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2024-2029) & (K Units)
Table 109. AstraZeneca Company Information
Table 110. AstraZeneca Description and Major Businesses
Table 111. AstraZeneca Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. AstraZeneca Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. AstraZeneca Recent Developments
Table 114. Merck & Co Company Information
Table 115. Merck & Co Description and Major Businesses
Table 116. Merck & Co Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Merck & Co Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Merck & Co Recent Developments
Table 119. GSK Company Information
Table 120. GSK Description and Major Businesses
Table 121. GSK Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. GSK Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. GSK Recent Developments
Table 124. Clovis Oncology Company Information
Table 125. Clovis Oncology Description and Major Businesses
Table 126. Clovis Oncology Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Clovis Oncology Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Clovis Oncology Recent Developments
Table 129. Pfizer Company Information
Table 130. Pfizer Description and Major Businesses
Table 131. Pfizer Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Pfizer Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Pfizer Recent Developments
Table 134. Zai Lab Company Information
Table 135. Zai Lab Description and Major Businesses
Table 136. Zai Lab Cancer Drug based on PARP Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Zai Lab Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Zai Lab Recent Developments
Table 139. Key Raw Materials Lists
Table 140. Raw Materials Key Suppliers Lists
Table 141. Cancer Drug based on PARP Inhibitor Distributors List
Table 142. Cancer Drug based on PARP Inhibitor Customers List
Table 143. Cancer Drug based on PARP Inhibitor Market Trends
Table 144. Cancer Drug based on PARP Inhibitor Market Drivers
Table 145. Cancer Drug based on PARP Inhibitor Market Challenges
Table 146. Cancer Drug based on PARP Inhibitor Market Restraints
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Drug based on PARP Inhibitor Product Picture
Figure 2. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Cancer Drug based on PARP Inhibitor Market Share by Type in 2022 & 2029
Figure 4. Lynparza Product Picture
Figure 5. Zejula Product Picture
Figure 6. Rubraca Product Picture
Figure 7. Talzenna Product Picture
Figure 8. Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Cancer Drug based on PARP Inhibitor Market Share by Application in 2022 & 2029
Figure 10. Ovarian Cancer
Figure 11. Breast Cancer
Figure 12. Other
Figure 13. Cancer Drug based on PARP Inhibitor Report Years Considered
Figure 14. Global Cancer Drug based on PARP Inhibitor Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Cancer Drug based on PARP Inhibitor Revenue 2018-2029 (US$ Million)
Figure 16. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Region (2018-2029)
Figure 18. Global Cancer Drug based on PARP Inhibitor Sales 2018-2029 ((K Units)
Figure 19. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Cancer Drug based on PARP Inhibitor Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Cancer Drug based on PARP Inhibitor Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Cancer Drug based on PARP Inhibitor Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Cancer Drug based on PARP Inhibitor Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Cancer Drug based on PARP Inhibitor Sales YoY (2018-2029) & (K Units)
Figure 25. China Cancer Drug based on PARP Inhibitor Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Cancer Drug based on PARP Inhibitor Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Cancer Drug based on PARP Inhibitor Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Cancer Drug based on PARP Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Cancer Drug based on PARP Inhibitor in the World: Market Share by Cancer Drug based on PARP Inhibitor Revenue in 2022
Figure 32. Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 34. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 35. Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 36. Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Cancer Drug based on PARP Inhibitor Revenue Share by Country (2018-2029)
Figure 42. US & Canada Cancer Drug based on PARP Inhibitor Sales Share by Country (2018-2029)
Figure 43. U.S. Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 46. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 47. Europe Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 48. Europe Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 49. Europe Cancer Drug based on PARP Inhibitor Revenue Share by Country (2018-2029)
Figure 50. Europe Cancer Drug based on PARP Inhibitor Sales Share by Country (2018-2029)
Figure 51. Germany Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 52. France Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 56. China Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 57. China Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 58. China Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 59. China Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 60. Asia Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 61. Asia Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 62. Asia Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 63. Asia Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 64. Asia Cancer Drug based on PARP Inhibitor Revenue Share by Region (2018-2029)
Figure 65. Asia Cancer Drug based on PARP Inhibitor Sales Share by Region (2018-2029)
Figure 66. Japan Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 70. India Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Cancer Drug based on PARP Inhibitor Sales Share by Country (2018-2029)
Figure 77. Brazil Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Cancer Drug based on PARP Inhibitor Revenue (2018-2029) & (US$ Million)
Figure 82. Cancer Drug based on PARP Inhibitor Value Chain
Figure 83. Cancer Drug based on PARP Inhibitor Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed